UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 2.124

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2019-09, Vol.381 (13), p.1201-1214

2019

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

Alimentary pharmacology & therapeutics, 2015-09, Vol.42 (5), p.504-514

2015

Volltextzugriff (PDF)

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Alimentary pharmacology & therapeutics, 2009-08, Vol.30 (3), p.210-226

2009

Volltextzugriff (PDF)

Do Stronger Wise‐Thinking Dispositions Facilitate Auditors' Objective Evaluation of Evidence When Assessing and Addressing Fraud Risk?

Contemporary accounting research, 2021-09, Vol.38 (3), p.1679-1711

2021

Volltextzugriff (PDF)

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2014, Vol.146 (1), p.85-95

2014

Volltextzugriff (PDF)

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2014-01, Vol.146 (1), p.96-109.e1

2014

Volltextzugriff (PDF)

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Gastroenterology (New York, N.Y. 1943), 2008-10, Vol.135 (4), p.1130-1141

2008

Volltextzugriff (PDF)

943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC

Gastroenterology (New York, N.Y. 1943), 2012-05, Vol.142 (5), p.S-161-S-161

2012

Volltextzugriff (PDF)

Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis

Value in health, 2014-05, Vol.17 (3), p.A40-A40

2014

Volltextzugriff (PDF)

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

The New England journal of medicine, 2005-12, Vol.353 (23), p.2462-2476

2005

Volltextzugriff (PDF)

Pasteurization of Discard Mycoplasma Mastitic Milk Used to Feed Calves: Thermal Effects on Various Mycoplasma

Journal of dairy science, 2000-10, Vol.83 (10), p.2285-2288

2000

Volltextzugriff (PDF)

Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy

Neurology, 2000-08, Vol.55 (4), p.527-532

2000

Volltextzugriff (PDF)

Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy

Brain and cognition, 2002-11, Vol.50 (2), p.194-206

2002

Volltextzugriff (PDF)

Risk for perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia

Transfusion (Philadelphia, Pa.), 2011-01, Vol.51 (1), p.82-91

2011

Volltextzugriff (PDF)

New Trends in Databases and Information Systems: ADBIS 2019 Short Papers, Workshops BBIGAP, QAUCA, SemBDM, SIMPDA, M2P, MADEISD, and Doctoral Consortium, Bled, Slovenia, September 8-11, 2019, Proceedings

1st ed. 2019., 2019

Volltextzugriff (PDF)

Broadband Networks, Smart Grids and Climate Change

1. Aufl., 2013

Volltextzugriff (PDF)

Advances in Databases and Information Systems: 23rd European Conference, ADBIS 2019, Bled, Slovenia, September 8-11, 2019, Proceedings

1st Edition 2019, 2019

Volltextzugriff (PDF)

PET measures of benzodiazepine receptors in progressive supranuclear palsy

Neurology, 2000-05, Vol.54 (9), p.1768-1773

2000

Volltextzugriff (PDF)

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i042-i043

2022

Volltextzugriff (PDF)

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

Gut, 2017-07, Vol.66 (Suppl 2), p.A23

2017

Volltextzugriff (PDF)

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S350-S351

2019

Volltextzugriff (PDF)

OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i025-i026

2022

Volltextzugriff (PDF)

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Journal of the Canadian Association of Gastroenterology, 2018-03, Vol.1 (suppl_1), p.242-243

2018

Volltextzugriff (PDF)

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

Neurology, 1997-07, Vol.49 (1), p.153-161

1997

Volltextzugriff (PDF)

1 – 25 von 2.124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.032)
Mit Volltextzugriff
(2.006)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(985)
Computer Science
(724)
Technology
(724)
Computer Science, Theory & Methods
(638)
Computer Science, Information Systems
(492)
Computer Science, Software Engineering
(241)
Life Sciences & Biomedicine
(239)
Computer Science, Artificial Intelligence
(226)
Humans
(184)
Computer Science, Interdisciplinary Applications
(155)
Network Hardware
(147)
Telecommunications
(115)
Expert Systems / Knowledge-Based Systems
(111)
User Interface Design & Usability
(111)
Exact Sciences And Technology
(100)
Applied Sciences
(99)
Female
(98)
Male
(98)
Computer Science; Control Theory; Systems
(97)
Software
(92)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ebook Central Perpetual and DDA
(1.270)
eBooks on EBSCOhost
(1.162)
IngentaConnect Journals
(784)
Springer Book Series
(577)
MEDLINE
(224)
EZB Electronic Journals Library
(194)
Journals@Ovid Full Text
(192)
De Gruyter eBooks
(175)
Standalone journals
(136)
Elsevier ScienceDirect Journals Collection
(112)
IngentaConnect Journals
(90)
Wiley Online Library All Obooks
(80)
Oxford Journals Online Current
(58)
Oxford Journals 2020 Medicine
(57)
Wiley-Blackwell Journals
(51)
Nature
(37)
Taylor & Francis eBooks A-Z
(34)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(32)
Springer journals
(27)
Wiley Online Library Full Collection 2018
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Do Stronger Wise‐Thinking Dispositions Facilitate Auditors' Objective Evaluation of Evidence When Assessing and Addressing Fraud Risk?

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC

Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Pasteurization of Discard Mycoplasma Mastitic Milk Used to Feed Calves: Thermal Effects on Various Mycoplasma

Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy

Patterns of neuropsychological performance in multiple system atrophy compared to sporadic and hereditary olivopontocerebellar atrophy

Risk for perioperative myocardial infarction and mortality in patients undergoing hip or knee arthroplasty: the role of anemia

New Trends in Databases and Information Systems: ADBIS 2019 Short Papers, Workshops BBIGAP, QAUCA, SemBDM, SIMPDA, M2P, MADEISD, and Doctoral Consortium, Bled, Slovenia, September 8-11, 2019, Proceedings

Broadband Networks, Smart Grids and Climate Change

Advances in Databases and Information Systems: 23rd European Conference, ADBIS 2019, Bled, Slovenia, September 8-11, 2019, Proceedings

PET measures of benzodiazepine receptors in progressive supranuclear palsy

OP36 Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study

OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn’s disease patients: results from im-uniti maintenance study

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study

OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12

A141 DIFFERENT INDUCTION RESPONSE CRITERIA DO NOT INFLUENCE 1 YEAR RESPONSE AND REMISSION RATES OF USTEKINUMAB 90MG Q8W IN PHASE III PROGRAM

Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease

Suchergebnisse filtern